ArticleIndian journal of psychiatry2025
Accelerated left dorsolateral prefrontal cortex transcranial magnetic stimulation for suicidality in patients with depressive disorders: A case series.
Article in Indian journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Suicidality in depression presents significant management challenges, with limited treatment options such as electroconvulsive therapy (ECT) and ketamine. Repetitive transcranial magnetic stimulation (rTMS) is an emerging intervention for such cases, particularly when ECT is contraindicated. This chart review examines the clinical outcomes of accelerated TMS (aTMS) targeting the left dorsolateral prefrontal cortex (DLPFC) for suicidality in depression patients. Cases: Six patients with depression and suicidality underwent aTMS targeting the left DLPFC between June 2024 to March 2025. Excitatory rTMS was administered using intermittent theta burst stimulation (iTBS) at 100%-120% of RMT. Treatment sessions were delivered over 6.17 ± 1.86 days, with a 60-min intersession interval to maximize cortical excitability. Symptom severity was assessed using the Columbia Suicide Severity Rating Scale (CSSRS) as the primary outcome measure and Hamilton Depression Rating Scale (HDRS). Significant reductions were observed in CSSRS scores (mean difference 11.87, 95% CI: 5.63, 18.0), corresponding to a 73.3% reduction in suicide severity. HDRS also improved significantly (mean difference 18.2, 95% CI: 13.50, 22.8), corresponding to a 73.1% reduction. All but one patient achieved a treatment response, and four patients met remission criteria. The interventions were well-tolerated, with no serious adverse effects. Conclusion: This study provides preliminary evidence supporting the efficacy, safety, and rapid reduction in suicidality with left DLPFC aTMS in depression. Randomized controlled trials are needed to validate these results, optimize treatment protocols, and assess the durability of clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.